The global biopharmaceutical CMO and CRO market size is accounted at USD 41.07 billion in 2025 and is forecasted to hit around USD 72.39 billion by 2034, representing a CAGR of 6.50% from 2025 to 2034. The North America market size was estimated at USD 3.13 billion in 2024 and is expanding at a CAGR of 6.86% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Source Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Biopharmaceutical CMO and CRO Market, by Product Type
7.1.1. Biologics
7.1.1.1. Market Revenue and Forecast
7.1.2. Biosimilars
7.1.2.1. Market Revenue and Forecast
8.1. Biopharmaceutical CMO and CRO Market, by Service
8.1.1. Contract Manufacturing
8.1.1.1. Market Revenue and Forecast
8.1.2. Contract Research
8.1.2.1. Market Revenue and Forecast
9.1. Biopharmaceutical CMO and CRO Market, by Source
9.1.1. Mammalian
9.1.1.1. Market Revenue and Forecast
9.1.2. Non-Mammalian
9.1.2.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product
10.1.2. Market Revenue and Forecast, by Service
10.1.3. Market Revenue and Forecast, by Source
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product
10.1.4.2. Market Revenue and Forecast, by Service
10.1.4.3. Market Revenue and Forecast, by Source
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product
10.1.5.2. Market Revenue and Forecast, by Service
10.1.5.3. Market Revenue and Forecast, by Source
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product
10.2.2. Market Revenue and Forecast, by Service
10.2.3. Market Revenue and Forecast, by Source
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product
10.2.4.2. Market Revenue and Forecast, by Service
10.2.4.3. Market Revenue and Forecast, by Source
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product
10.2.5.2. Market Revenue and Forecast, by Service
10.2.5.3. Market Revenue and Forecast, by Source
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product
10.2.6.2. Market Revenue and Forecast, by Service
10.2.6.3. Market Revenue and Forecast, by Source
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product
10.2.7.2. Market Revenue and Forecast, by Service
10.2.7.3. Market Revenue and Forecast, by Source
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product
10.3.2. Market Revenue and Forecast, by Service
10.3.3. Market Revenue and Forecast, by Source
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product
10.3.4.2. Market Revenue and Forecast, by Service
10.3.4.3. Market Revenue and Forecast, by Source
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product
10.3.5.2. Market Revenue and Forecast, by Service
10.3.5.3. Market Revenue and Forecast, by Source
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product
10.3.6.2. Market Revenue and Forecast, by Service
10.3.6.3. Market Revenue and Forecast, by Source
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product
10.3.7.2. Market Revenue and Forecast, by Service
10.3.7.3. Market Revenue and Forecast, by Source
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product
10.4.2. Market Revenue and Forecast, by Service
10.4.3. Market Revenue and Forecast, by Source
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product
10.4.4.2. Market Revenue and Forecast, by Service
10.4.4.3. Market Revenue and Forecast, by Source
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product
10.4.5.2. Market Revenue and Forecast, by Service
10.4.5.3. Market Revenue and Forecast, by Source
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product
10.4.6.2. Market Revenue and Forecast, by Service
10.4.6.3. Market Revenue and Forecast, by Source
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product
10.4.7.2. Market Revenue and Forecast, by Service
10.4.7.3. Market Revenue and Forecast, by Source
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product
10.5.2. Market Revenue and Forecast, by Service
10.5.3. Market Revenue and Forecast, by Source
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product
10.5.4.2. Market Revenue and Forecast, by Service
10.5.4.3. Market Revenue and Forecast, by Source
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product
10.5.5.2. Market Revenue and Forecast, by Service
10.5.5.3. Market Revenue and Forecast, by Source
11.1. Lonza
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. JRS Pharma
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Samsung Biologics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. CMC Biologics
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. TOYOBO Co. Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. RentschlerBiotechnologie
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. FUJIFILM Diosynth Biotechnologies
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. WuXi Biologics
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Patheon
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BoehringerIngelheim
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. PRA Health Sciences
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. LabCorp
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample